Abstracts

Embargo* Policy

• Abstracts submitted to the ISCT 2019 Annual Meeting are embargoed from other scientific journals or conference presentations from the time of submission.
• For the abstract to be eligible for presentation at the ISCT 2019 Annual Meeting, information contained within, as well as additional data and information to be presented about the content, may not be published elsewhere or presented in another journal or conference before the abstract has been published/presented at the ISCT 2019 Annual Meeting.
• Authors must notify ISCT if, after the submission deadline, the submitted abstract is accepted for publication elsewhere or will be presented before the ISCT 2019 Annual Meeting. Publication before the meeting may result in the abstract being removed from the meeting.
• If the Embargo Policy is violated, the abstract may be withdrawn by ISCT from presentation at the ISCT 2019 Annual Meeting and from publication in the final program.

*An embargo means that information from any abstract or presentation may not be presented or published in another journal or conference before the embargo date and time.

Fees

There are no fees associated with submitting an abstract. Those presenting abstracts will be responsible for their own travel and meeting expenses.

Publication 

Accepted abstracts will be published in a supplemental version of Cytotherapy, the official journal of ISCT.

Notifications

All selected presenters have now been notified of their abstracts acceptance for poster, elevator pitch and poster, or oral presentation at ISCT 2019.

If you submitted an abstract to the ISCT 2019 Annual Meeting and have not yet received a response, please send inquiries to sophie@celltherapysociety.org.

NEW for 2019 Elevator Pitch Abstract Presentations will allow a select number of poster presenters to showcase their abstract by way of a 2 minute ‘rapid-fire’ oral presentation.

Withdrawal Policy

Please note that the deadline to withdraw abstracts from publication has now passed. Abstracts can be withdrawn from conference participation but will be included in the supplemental publication of Cytotherapy.

Awards

Early Stage Professionals Abstract Award Winners

• Sophia Schreiber, MSc, Technical University of Munich (Germany)
  Abstract: Characterization of MHC class II-restricted T-cell receptors for T-cell therapy of HBV infection
  Presentation: May 30, Plenary Satellite 1b – Immunotherapy Oral Abstract Presentations II
• David Bishop, BMedSc(Hons), MBBS, FRACP FRCPA, Westmead Hospital (Australia)
  Abstract: Matched Sibling Donor-Derived Piggybac CAR19 T Cells Induce Remission Of Relapsed/Refractory CD19+ Malignancy Following Haematopoietic Stem Cell Transplant
  Presentation: May 30, Plenary Satellite 1a – Immunotherapy Oral Abstract Presentations I
• Michael Bellio, PhD, University of Miami (United States)
  Abstract: Bioreactor Produced Wharton’s Jelly Mesenchymal Stem Cell- Derived Exosomes Prevent Lung Injury in a Pre-clinical Model of Bronchopulmonary Dysplasia
  Presentation: June 1, Chief Scientific Officer Abstract Showcase

Technologist Abstract Awards

• Kaori Okada, PharmD, University of California San Francisco (United States)
  Abstract: Development of a large-scale H3.3K27M-specific TCR-transduced T cell manufacturing method for adoptive cell therapy in HLA-A2+ patients with diffuse midline glioma
  Poster Presentation
• Kap-Hyoun Ko, PhD, Sydney Children’s Hospital (Australia)
  Abstract: Enumeration of primitive haematopoietic progenitor cells to improve the quality of cord blood product testing
  Presentation: May 31, Elevator Pitch & Poster Presentation
• Sharon Ng Wah Suet, MSc, Genepath Technology (China)
  Abstract: Ultrastructure Of Cytokine Induced Human Natural Killer Cells
  Presentation: May 31, Elevator Pitch & Poster Presentation

Top Scoring Abstract Award

• Yohei Sato, MD, PhD, Stanford University (United States)
  Abstract: Immunoregulatory cell therapy with lentiviral-mediated FOXP3 converted CD4+ T cells into Treg cells: towards the proof-of-concept application in IPEX syndrome
  Presentation: June 1, Plenary Satellite 5a – Gene Therapy

Emerging Economy Abstract Award

• Ting Zhang, PhD, The General Hospital of PLA (China)
  Abstract: Phase I dose escalating trail of GPC3-targeted CAR-T cells by intratumor injection for Advanced Hepatocellular carcinoma
  Presentation: May 30, Plenary Satellite 1a – Immunotherapy Oral Abstract Presentations I

Best Poster Award

• To be selected on site